Press "Enter" to skip to content

FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

FDA approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults with treatment-resistant depression

Also Read:   UPDATE: The FDA Warns that Biotin May Interfere with Lab Tests: FDA Safety Communication